How to Develop Strong Evidence to Enable Optimal Access Recording

Home / Intelligence / Webinars / How to Develop Strong Evidence to Enable Optimal Access Recording

Available On Demand

Communicating a compelling value story to clinicians and payers is key to launching a product successfully and optimizing value throughout the product lifecycle.

  • But how exactly does one generate evidence that will educate stakeholders on the disease state, shape the future market and support your value narrative?
  • What are the ‘nuts and bolts’ of designing and conducting such studies?
  • How do you distill down to the key value messages from a complex data set to be most impactful to clinical and payer audiences?

Learn how Burden of Illness studies are conducted and how this study type could support your disease areas! The Trinity team will highlight the importance of evidence generation through the lens of a scientific Burden of Illness study that we recently conducted with a global pharma company. Beyond the scientific implications of studies of this kind, we will delve into the real-world applications of this evidence from a market access perspective.

Please complete the form to watch our Trinity Webinar: How to Develop Strong Evidence to Enable Optimal Access.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email

Related Intelligence


Rise with the Waves: UK – Now and Beyond – Four Policy Trends That May Shape Pharma’s Future 

Executive Summary The global payer landscape is rapidly evolving and is expected to continuously impact manufacturers’ decisions about new launches, portfolio management, trial design and importantly, pricing and market access strategy. In the UK, several policy reforms have been introduced which are expected to improve patient access while balancing financial healthcare sustainability and overall market […]

 Read More


HTA Vision—Implications Beyond the Rating

June 13, 2024 | 1:00 – 1:45 PM ET

An additional session will be offered on June 18, 2024 at 15:00 – 15:45 CET – Europe/Berlin A number of critical manufacturer activities are informed by understanding health technology assessment (HTA) agency behavior across geographies and therapeutic areas—from pipeline, business development and licensing to launch planning preparation through to lifecycle management strategy. Join Max Hunt, […]

 Sign Up Now


Rise with the Waves: France – Accelerating Pricing and Market Access: Two Policies Shaping Pharma’s Future

Executive Summary The latest publication of new reimbursement regulations in the French Social Security Financing Act (PLFSS 2024), coupled with the recent approval of HEMGENIX® through the direct access scheme in France this past December, underline continued efforts in France to innovate its healthcare system. The 2024 PLFSS emphasizes: The direct access scheme is expected […]

 Read More